Alzheimer’s Disease

Have you or a loved one been diagnosed with Alzheimer’s disease? Are you experiencing troubles with your memory? You may be eligible for a no-cost memory screen to participate in a clinical research trial.

Below you’ll find the clinical trials we are currently enrolling participants in or will be soon.

• A Clinical Study of MK-2214 in People With Early Alzheimer’s Disease (MK-2214-004)
  Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer’s disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person’s ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.
  ClinicalTrials.gov Identifier: NCT07033494
• A Study of Remternetug (LY3372993) in Early Alzheimer’s Diseae (TRAILRUNNER-ALZ 3)
  • The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer’s disease occurring in participants receiving study drug compared to placebo.
  • ClinicalTrials.gov Identifier: NCT06653153
• Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia (Bio-Hermes-002).
  • The purpose of the 120-day cross-sectional study will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images. 
  • ClinicalTrials.gov Identifier: NCT06584357
• Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer’s Disease (TargetTau-1)
  • The purpose of this study is to assess the effectiveness, safety, and tolerability of a drug (BMS-986446) in participants with Early Alzheimer’s disease. This study is for those with Mild Cognitive Impairment (MCI) or Mild Alzheimer’s disease.
  • ClinicalTrials.gov Identifier: NCT06268886